All In Biotech

Drug Trial Radar · NCT04716231

Atacicept in Subjects With IgA Nephropathy

A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With IgA Nephropathy (IgAN)

Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 428 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

428

Actual

Start

Jun 29, 2023

Primary completion

May 15, 2025

Study completion Jul 2028

Sponsor

Lead sponsor
Vera Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jan 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)

Conditions

  • IgA Nephropathy
  • Berger Disease

Interventions

  • AtaciceptBiological

    Once weekly subcutaneous (SC) injections by prefilled syringe

  • Placebo to match AtaciceptOther

    Once weekly subcutaneous (SC) injections by prefilled syringe

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Change From Baseline in Urine Protein to Creatinine Ratio (UPCR)Time frame: 36 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ORIGIN 3 Global Site Contact Information

    Brisbane, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.